Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Bausch Health Companies Inc. Common Stock (NY:BHC)

8.340 +0.830 (+11.05%)
Official Closing Price Updated: 7:00 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bausch Health Companies Inc. Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Bausch Health to Announce Second-Quarter 2023 Results on Aug. 3
Via ACCESSWIRE
Salix Announces 2023 Gastrointestinal Health Scholars Program Winners
Via ACCESSWIRE
Breather For Carl Icahn: Revised Loan Agreements and Recovery Strategy Post Short-Seller Attack
Activist investor Carl Icahn has been struggling to recover after a short-seller attack led to a 40% drop in his investment company's shares, Icahn Enterprises L.P. (NASDAQ: IEP), alarming major banks... 
Via Benzinga
Why Shares of Bausch Health Jumped on Friday
Global investment powerhouse KKR will be providing the healthcare company with increased liquidity. 
Via The Motley Fool
OraPharma to Participate in the First-Ever Research and Technology Pavilion Sponsored by Pacific Dental Services(R) at the American Dental Hygienists' Association (ADHA(R)) Annual Conference
Via ACCESSWIRE
Bausch Health Enters Into $600 Million Financing Facility With KKR
Via ACCESSWIRE
Salix to Present Data from XIFAXAN(R) (Rifaximin) Clinical Research at EASL's International Liver Congress(TM) 2023
Via ACCESSWIRE
Why Bausch Health Companies Stock Is Tanking Today
The never-ending saga over generic Xifaxan is weighing on the drugmaker's stock today. 
Via The Motley Fool
Bausch + Lomb Poised To Boost Presence In Growing Market With Potential $1.75B Drug Acquisition Deal From Novartis
Bausch + Lomb Corporation (NYSE: BLCO) has agreed to acquire 'front of eye' ophthalmology assets for $1.75 billion in upfront cash, plus additional milestone payments from Novartis AG (NYSE: 
Via Benzinga
Bausch Health’s Bausch + Lomb to Acquire Novartis’ XIIDRA(R)
Via ACCESSWIRE
Benzinga's Top Ratings Upgrades, Downgrades For June 16, 2023
 
Via Benzinga
Coinbase, Blue Bird, Tingo Group And Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded mixed, with the Nasdaq Composite rising around 0.2% on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Why Shares of Bausch Health Soared Wednesday
The company won a big patent fight with a generic-drug maker. 
Via The Motley Fool
Bausch Health Announces 2023 Annual Meeting of Shareholder Results
Via ACCESSWIRE
Why THOR Industries Shares Are Trading Higher By 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Recruiter.com Group, Inc. (NASDAQ: RCRT) shares jumped 114% to $0.41. Recruiter.com signed a definitive agreement for planned purchase of fintech assets of GoLogiq. 
Via Benzinga
Bausch Health Responds to Norwich's ANDA Tentative Approval and Lawsuit Against United States Food and Drug Administration
Via ACCESSWIRE
Zoetis Declares New Dividend, Hinting At Undervaluation
Zoetis shareholders woke up to news of JAB's acquisition of Pumpkin, a per insurance platform where Zoetis owns a minority stake. 2023 outlooks suggest a rally 
Via MarketBeat
Salix Pharmaceuticals to Deliver Podium Presentation at Digestive Disease Week(R) 2023
Via ACCESSWIRE
Why Bausch Health Stock Is Tumbling Today
Bausch Health Companies Inc (NYSE: BHC) reported Q1 FY23 revenues of $1.94 billion, up 1% Y/Y, up 4% organic basis, missing the consensus  
Via Benzinga
Bausch Health Options Traders: Stock Will Remain Below This Level Through July Expiration
Bausch Health Companies Inc. (NYSE: BHC) shares rose sharply on Wednesday. 
Via Benzinga
New Clinical Study Suggests the Use of OraPharma’s ARESTIN(R) (minocycline HCl) Microspheres, 1mg May Decrease Certain Pathogens in Adults with Periodontitis
Via ACCESSWIRE
U.S. District Court Upholds Final Judgment for XIFAXAN(R) 550 mg That Prevents FDA Approval of Norwich’s Abbreviated New Drug Application Until 2029
Via ACCESSWIRE
Bausch Health Observes Mental Health Awareness Month
Via ACCESSWIRE
Recap: Bausch Health Companies Q1 Earnings
 
Via Benzinga
US Stocks Set For Mixed Open As Banking Jitters Dampen Apple Earnings Buzz: Analyst Advises 'Cautious Optimism'
With so much going on in the banking space, sentiment continues to remain jittery. The index futures point to a mixed opening on Thursday, as the tech space exuded optimism ahead of Apple, Inc.’s... 
Via Benzinga
Bausch Health Announces First-Quarter 2023 Results
Via ACCESSWIRE
Why Synaptics Shares Are Trading Lower By 17%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Qurate Retail, Inc. (NASDAQ: QRTEB) shares jumped 89.3% to $7.44. 
Via Benzinga
New Artificial Intelligence Tool Can Diagnose Colon Cancer
A new artificial intelligence (AI) model developed by Harvard Medical School and Taiwan’s National Cheng Kung University could provide much-needed clarity to clinicians presenting prognoses and... 
Via PressReach
Topics Artificial Intelligence Death
Ortho Dermatologics Announces U.S. Food and Drug Administration New Drug Application Filing Acceptance for Investigational Acne Treatment IDP-126 Gel
Via ACCESSWIRE
Unlocking Xenon Pharmaceuticals $1B Potential: Analyst Cites Anti-Epileptic Candidate's Untapped Value
Cantor Fitzgerald has initiated coverage on Xenon Pharmaceuticals Inc (NASDAQ: XENE) with an Overweight rating and a  
Via Benzinga
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.